First AREDS 2 AMD product hits market

Article

Visual Advantage by Macular Health is the first product available to the public featuring the new AREDS 2 formula for preventing vision loss due to AMD.

 

Birmingham, AL-Visual Advantage by Macular Health has become the first product available to the public featuring the new AREDS 2 formula for preventing vision loss due to AMD.

Macular Health's original supplement formulation was modeled after the results of AREDS I, released in 2001. However, Jeffery McAnnally, president and chief executive officer of Macular Health, along with John O. Mason, III, MD, a retina surgeon from the University of Alabama at Birmingham Callahan Eye Foundation Hospital, modified the formula slightly to include lutein and zeaxanthin, which were ultimately proven by AREDS 2 to be the keys to the supplement's effectiveness.

Macular Health's Visual Advantage is specially formulated in the United States by an FDA inspected and GMP (Good Manufacturing Practices) compliant facility.

Recent Videos
Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.
Neda Gioia, OD, CNS, FOWNS, details the positive feedback gained so far from other optometrists that have been prescribing the NutriTears supplement to their dry eye patients.
Damaris Raymondi, OD, FAAO, highlighted the importance of building patient-doctor trust to learn about these practices, which can include non-traditional treatments like chamomile or manuka honey eye drops.
Noreen Shaikh, OD, Magdalena Stec, OD, FAAO, and Brenda Bohnsack, MD, PhD, emphasize that collaboration and communication are key to proper diagnosis and treatment.
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Kerry Giedd, OD, MS, FAAO, was 1 of 20 investigators around the country for a study evaluating the daily disposable contact lens.
According to A. Paul Chous, MA, OD, FAAO, optometrists have an important opportunity to educate patients in their chairs about diabetes.
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
Jessica Steen, OD, FAAO, Dipl-ABO, discussed ophthalmic considerations for patients undergoing treatment with antibody drug conjugates for gynecologic cancers at this year's conference.
A. Paul Chous, MA, OD, FAAO, details a presentation on this year's updates on diabetes given at this year's Academy meeting
© 2024 MJH Life Sciences

All rights reserved.